Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry M Collins

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Nuclear Medicine and Biology|December 21, 2002
Imaging [18F]FAU [1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) uracil] in dogsHaihao Sun, Jerry M Collins, Thomas J Mangner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2005
Imaging DNA synthesis in vivo with 18F-FMAU and PETHaihao Sun, Thomas J Mangner, Jerry M Collins, et al.
Pharmacogenomics|June 24, 2004
Pharmacogenomic data submissions to the FDA: clinical pharmacology case studiesGualberto Ruaño, Jerry M Collins, Andrew J Dorner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 9, 2004
Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancerHaihao Sun, Andrew Sloan, Thomas J Mangner, et al.
Cancer Research|April 26, 2022
ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo StudiesMelinda G Hollingshead, Nathaniel Greenberg, Michelle Gottholm-Ahalt, et al.
Cancer Chemotherapy and Pharmacology|August 6, 2013
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomasShivaani Kummar, Martin E Gutierrez, Lawrence W Anderson, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactionsLawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|October 19, 2016
Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: <sup>18</sup>F-FAU, <sup>18</sup>F-FMAU, and <sup>18</sup>F-FLTChristopher I McHugh, Jawana M Lawhorn-Crews, Dipenkumar Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing RadiationTimothy Kinsella, Howard Safran, Susan Wiersma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 5, 2005
Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogsSridhar Nimmagadda, Thomas J Mangner, Haihao Sun, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Nuclear Medicine and Biology|December 21, 2002
Imaging [18F]FAU [1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) uracil] in dogsHaihao Sun, Jerry M Collins, Thomas J Mangner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2005
Imaging DNA synthesis in vivo with 18F-FMAU and PETHaihao Sun, Thomas J Mangner, Jerry M Collins, et al.
Pharmacogenomics|June 24, 2004
Pharmacogenomic data submissions to the FDA: clinical pharmacology case studiesGualberto Ruaño, Jerry M Collins, Andrew J Dorner, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 9, 2004
Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancerHaihao Sun, Andrew Sloan, Thomas J Mangner, et al.
Cancer Research|April 26, 2022
ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo StudiesMelinda G Hollingshead, Nathaniel Greenberg, Michelle Gottholm-Ahalt, et al.
Cancer Chemotherapy and Pharmacology|August 6, 2013
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomasShivaani Kummar, Martin E Gutierrez, Lawrence W Anderson, et al.
Cancer Chemotherapy and Pharmacology|May 17, 2005
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactionsLawrence W Anderson, Jerry M Collins, Raymond W Klecker, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|October 19, 2016
Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: <sup>18</sup>F-FAU, <sup>18</sup>F-FMAU, and <sup>18</sup>F-FLTChristopher I McHugh, Jawana M Lawhorn-Crews, Dipenkumar Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2019
Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing RadiationTimothy Kinsella, Howard Safran, Susan Wiersma, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 5, 2005
Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogsSridhar Nimmagadda, Thomas J Mangner, Haihao Sun, et al.
Pageof 4